Mallinckrodt plc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Columbia on behalf of investors who purchased Mallinckrodt plc (NYSE: MNK) securities between July 14, 2014, and January 18, 2017.
According to the complaint, throughout the Class Period, Mallinckrodt and its acting President and Chief Executive Officer, Mark Trudeau, misrepresented the efficacy of Mallinckrodt’s business model and its ability to maintain sustainable revenue. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that Mallinckrodt engaged in unlawful anticompetitive practices to maintain H.P. Acthar Gel’s (“Acthar”) monopoly status as the only FDA-approved therapeutic preparation of adrenocorticotropic hormone and that Mallinckrodt’s increasing reliance on Medicare and Medicaid meant that the Company’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for the drug by taxpayers.
“Mallinckrodt plc”
If you suffered a loss in Mallinckrodt you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.